Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grippostad Day
- Development stage
- Unknown
- Lead developer
- STADA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Grippostad Day is an oral combination medication developed by STADA Arzneimittel for the symptomatic relief of the common cold and influenza. The formulation consists of three small molecule active ingredients: paracetamol (300 mg), caffeine (25 mg), and phenylephrine hydrochloride (5 mg). Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin G/H synthase 1 and 2 (COX-1 and COX-2). Caffeine acts as an adenosine A1 and A2a receptor antagonist and a non-selective phosphodiesterase inhibitor, which potentiates the analgesic effects of paracetamol and helps counteract the fatigue associated with viral infections. Phenylephrine hydrochloride is a sympathomimetic decongestant that targets alpha-1 adrenergic receptors to reduce nasal mucosal swelling. The drug is specifically indicated for daytime use to alleviate fever, aches, pains, sore throat, and nasal congestion in adults and adolescents aged 12 years and older.
- Brand names
- Grippostad Day
- Other names
- paracetamol + caffeine + phenylephrine hydrochloride
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADRA1A (α1A)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on Grippostad Day.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grippostad Day.